Evidence map›Paper›PMID 29207107›Full record

ArticleMolecular medicine reports2018

Modular organization of a hypocretin gene minimal promoter.

Adriana Sánchez-García, Griselda A Cabral-Pacheco, Viviana C Zomosa-Signoret, Rocío Ortiz-López, Alberto Camacho, Paulo M Tabera-Tarello, José A Garnica-López, Román Vidaltamayo

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Exploring the Toxicity and Therapeutic Potential ofInternational journal of molecular sciences · 2025
    Article
  2. Neurobiology of sleep (Review).Experimental and therapeutic medicine · 2021
    Review
  3. Involvement of PLAGL1/ZAC1 in hypocretin/orexin transcription.International journal of molecular medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Adriana Sánchez-GarcíaDepartment of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, NL 64460, Mexico.
Griselda A Cabral-PachecoDepartment of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, NL 64460, Mexico.
Viviana C Zomosa-SignoretDepartment of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, NL 64460, Mexico.
Rocío Ortiz-LópezGenomics Unit, Center for Research and Development in Health Sciences, Universidad Autonoma de Nuevo Leon, Monterrey, NL 64460, Mexico.
Alberto CamachoDepartment of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, NL 64460, Mexico.
Paulo M Tabera-TarelloDepartment of Basic Science, School of Health Sciences, Universidad de Monterrey, San Pedro Garzia, NL 66238, Mexico.
José A Garnica-LópezDepartment of Basic Science, School of Health Sciences, Universidad de Monterrey, San Pedro Garzia, NL 66238, Mexico.
Román VidaltamayoDepartment of Basic Science, School of Health Sciences, Universidad de Monterrey, San Pedro Garzia, NL 66238, Mexico.
Universidad Autónoma de Nuevo León · MXUniversity of Monterrey · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Orexins or hypocretins are neurotransmitters produced by a small population of neurons in the lateral hypothalamus. This family of peptides modulates sleep‑wake cycle, arousal and feeding behaviors; however, the mechanisms regulating their expression remain to be fully elucidated. There is an interest in defining the key molecular elements in orexin regulation, as these may serve to identify targets for generating novel therapies for sleep disorders, obesity and addiction. Our previous studies showed that the expression of orexin was decreased in mice carrying null‑mutations of the transcription factor early B‑cell factor 2 (ebf2) and that the promoter region of the prepro‑orexin (Hcrt) gene contained two putative ebf‑binding sites, termed olf‑1 sites. In the present study, a minimal promoter region of the murine Hcrt gene was identified, which was able to drive the expression of a luciferase reporter gene in the human 293 cell line. Deletion of the olf1‑site proximal to the transcription start site of the Hcrt gene increased reporter gene expression, whereas deletion of the distal olf1‑like site decreased its expression. The lentiviral transduction of murine transcription factor ebf2 cDNA into 293 cells increased the gene expression driven by this minimal Hcrt‑gene promoter and an electrophoretic mobility shift assays demonstrated that the distal olf1‑like sequence was a binding site for ebf2.

Indexed as

Promoter Regions, GeneticAnimalsBase SequenceBasic Helix-Loop-Helix ProteinsCell LineGene ExpressionGenes, ReporterHumansMiceOrexinsTransfectionBasic Helix-Loop-Helix ProteinsEbf2 protein, mouseHcrt protein, mouseOrexins

Identifiers

PMID29207107
PMCPMC5783473
OpenAlexW2770319702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.